Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study

Background and Aim This study aimed to clarify the efficacy and safety of 48‐week pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110 patients diagnosed with MASLD complicated by dyslipidemia rece...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JGH Open 2024-04, Vol.8 (4), p.e13057-n/a
Hauptverfasser:	Ono, Hiroki, Atsukawa, Masanori, Tsubota, Akihito, Arai, Taeang, Suzuki, Kenta, Higashi, Tetsuyuki, Kitamura, Michika, Shioda‐Koyano, Kaori, Kawano, Tadamichi, Yoshida, Yuji, Okubo, Tomomi, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Nagao, Mototsugu, Iwabu, Masato, Iwakiri, Katsuhiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Alcohol use Aspartate Biochemistry Biopsy Care and treatment Cholesterol Collagen Diabetes Enzymes Females Fenofibrate Glucose Health aspects High density lipoprotein homeostasis model assessment‐insulin resistance Insulin resistance Laboratories Lipids Liver cirrhosis Liver diseases liver fibrosis Low density lipoprotein Metabolic disorders metabolic dysfunction‐associated steatotic liver disease non‐alcoholic fatty liver disease Original Patients pemafibrate Performance evaluation Phosphatases Protein binding Type 2 diabetes Ultrasonic imaging Variables Vitamin E
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and Aim This study aimed to clarify the efficacy and safety of 48‐week pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110 patients diagnosed with MASLD complicated by dyslipidemia received pemafibrate at a dose of 0.1 mg twice daily for 48 weeks. Results The participants were 54 males and 37 females, with a median age of 63 (52–71) years. Besides improvement in lipid profile, significant reductions from baseline to 48 weeks of treatment were found in liver‐related enzymes, such as aspartate aminotransferase, alanine aminotransferase (ALT), gamma‐glutamyl transpeptidase, and alkaline phosphatase (P
ISSN:	2397-9070 2397-9070
DOI:	10.1002/jgh3.13057